Harvard College

Pfizer Corporation

Other

Children's Medical Center Corporation

Elias James Corey

Thomas K Schaaf

Jasjit S Bindra

Moses J Folkman

David Gin

Philip C Hogan

Neil T Chen

Compounds and oral pharmaceutical compositions which neutralize microbially-produced electrophilic carbonyl species, comprising:

Prevention and treatment of human metabolic syndrome including type 2 diabetes, steatohepititis and related conditions using non-absorbable, orally administered compounds

The present invention is directed to the synthesis and characterization of compounds having the formula:

Synthetic analogs of ecteinascidin-743

Disclosed herein are analogs of Salinosporamide A, having the Formulae Ia-IVa as follows: Like Salinosporamide A, the compounds of the present invention will inhibit the proteasome, an intracellular enzyme complex that destroys proteins the cell no longer needs. Without the proteasome, proteins would build up and clog cellular machinery. Fast-growing cancer cells make especially heavy use of the proteasome, so thwarting its action is a compelling drug strategy.

Analogs of Salinosporamide A

Disclosed is a total synthesis of a biologically active &#x3b2;-Lactam&#x2014;Compound 3, which is related to Salinosporamide A and Omuralide, both structurally and by its activity as a proteasome inhibitor. Also disclosed are proteasome inhibiting compounds having the formula: wherein:

Proteasome inhibiting &#x3b2;-lactam compounds

A simple and effective stereocontrolled synthesis of salinosporamide A(1) has been developed which follows the pathway outlined in the FIGURE. The process, the first total synthesis of salinosporamide A, is capable of providing the compound in substantial quantities for further biological studies. In addition to the method of Scheme I, the present invention also includes several novel synthetic intermediate compounds, several intermediate steps of the preferred synthetic process; and the uses of these compounds in the preparation of synthetic derivatives of the compound Salinosporamide A. Salinosporamide A is of special interest as a synthetic target because of its protein in vitro cytotoxic activity against many tumor cell lines (ICvalues of 10 nM or less).

Simple stereocontrolled synthesis of salinosporamide A

An efficient process is described for the synthesis of 5, a key intermediate for the synthesis of the potent antitumor agents ecteinascidin 743 (1) and phthalascidin (2) from the readily available building blocks 3b and 4.

Synthetic process for an intermediate for ecteinascidin and phthalascidin compounds

The present invention is directed to the synthetic processes outlined in Schemes 1, 2 and 3, to the novel intermediates recited therein, and to the uses of these compounds as synthetic precursors to the pseudopterosins. Other embodiments and aspects of the present invention include the novel synthetic procedures described herein. Scheme I is shown below:

Synthesis of pseudopterosin compounds

The present invention is directed to the synthesis and characterization of compounds having the formula: wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently selected from the group consisting of H, OH, OR', SH, SR', SOR', SO.sub.2 R', NO.sub.2, NH.sub.2, NHR', N(R).sub.2, NHC(O)R', CN, halogen, .dbd.O, C(.dbd.O)H, C(.dbd.O)R', CO.sub.2 H, CO.sub.2 R', C.sub.1 -C.sub.12 alkyl, C.sub.2 -C.sub.12 alkenyl, C.sub.2 -C.sub.12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaromatic;

The present invention is directed to a synthetic process for the formation of ecteinascidin compounds and related structures, such as the saframycins. In one particularly preferred embodiment, the present invention provides a synthetic route for the formation of ecteinascidin 743 (1), ##STR1## an exceedingly potent and rare marine-derived antitumor agent which is slated for clinical trials. The process of this invention is enantio- and stereocontrolled, convergent and short. Also disclosed are novel process intermediates, useful not only in the total synthesis of ecteinascidin 743, but also other known ecteinascidin compounds, including derivatives and analogs thereof.

Process for producing ecteinascidin compounds

Anigiogenesis is controlled by administering to a mammal an effective amount of an inhibitor of arylsulfatase. Preferably, the arylsulfatase inhibitor is administered in a pharmaceutically acceptable vehicle in combination with an angiostatic steroid and (optionally) heparin (by which term we include all forms and fragments of heparin having the desired angiostatic activity). Hydrocortisone is one specifically preferred steroid. The preferred arylsulfatase inhibitor is a carboxylic acid ester or a sulfuric acid ester of a benzylic alcohol, most preferably the esters defined more particularly below. The arylsulfatase inhibitor is preferably administered locally to the tissue experiencing undesired angiogenesis. Arylsulfatase inhibitor and an angiostatic steroid are included in a pharmaceutically acceptable vehicle, preferably also with heparin, to yield an angiostatic thereapeutic composition. Also, coagulation of blood is inhibited by adding a composition comprising an arylsulfatase inhibitor and heparin to the blood. Such compositions are also disclosed.

Arylsulfatase inhibition and potentiation of angiostatic steroids and

Chiral 1,3,2-oxazaborolidines and tetrahydro-1,3,2-oxazaborines are effective catalysts for the borane reduction of prochiral ketones to optically active alcohols.

Enantioselective reduction of ketones

A new synthesis of key prostaglandin precursors and intermediates employed in their preparation. The novel synthetic sequence of this invention is shorter and more efficient than those previously employed to prepare to key intermediate.

Growing community of inventors

Cambridge, MA, United States of America

Elias James Corey